Investors / filer profile

Fairmount Funds Management LLC

active in 9 companies · 2 of 4 positions beat the S&P ~6mo later

Pro
Bought: Pro
Sold: 21
Filings: 9
Companies: 2026-09-03
Last filed

EDGAR · CIK 0001802528 ↗

Track record

How each disclosed position did against the S&P ~6 months later

The outcome curve and every position's resultPro →

+59.0%

median move per position

+9.8%

S&P 500 median, same spans

2 of 4

beat the S&P ~6mo later

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$59.25M bought · −$960.60M sold

All filings on record

Every Form 4 transaction we track for this filer


APGEApogee Therapeutics, Inc.	Return — · 51,166 sh	2026-09-03	—
APGEApogee Therapeutics, Inc.	Return — · 51,166 sh	2026-09-03	—
APGEApogee Therapeutics, Inc.	Return — · 340,855 sh	2026-09-03	—
APGEApogee Therapeutics, Inc.	Exercise $454.7K · 10,370 sh	2026-08-07	—
APGEApogee Therapeutics, Inc.	Exercise $541.2K · 31,838 sh	2026-08-07	—
ORKAOruka Therapeutics, Inc.	Sell $300.01M · 3,553,410 sh	2026-07-01	—
ORKAOruka Therapeutics, Inc.	Convert — · 3,553,410 sh	2026-07-01	—
SYRESpyre Therapeutics, Inc.	Sell $399.66M · 4,684,781 sh	2026-06-23	—
SYRESpyre Therapeutics, Inc.	Convert — · 666,680 sh	2026-06-23	—
DMRADamora Therapeutics, Inc.	Exercise — · 2,904,000 sh	2026-02-09	—

APGEReturn

2026-09-03 · Apogee Therapeutics, Inc.

51,166

—

APGEReturn

2026-09-03 · Apogee Therapeutics, Inc.

51,166

—

APGEReturn

2026-09-03 · Apogee Therapeutics, Inc.

340,855

—

APGEExercise

2026-08-07 · Apogee Therapeutics, Inc.

$454.7K

—

APGEExercise

2026-08-07 · Apogee Therapeutics, Inc.

$541.2K

—

ORKASell

2026-07-01 · Oruka Therapeutics, Inc.

$300.01M

—

ORKAConvert

2026-07-01 · Oruka Therapeutics, Inc.

3,553,410

—

SYRESell

2026-06-23 · Spyre Therapeutics, Inc.

$399.66M

—

SYREConvert

2026-06-23 · Spyre Therapeutics, Inc.

666,680

—

DMRAExercise

2026-02-09 · Damora Therapeutics, Inc.

2,904,000

—

Newest 10 of 21 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.